We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Threadneedle European Select Fund research update

Investments can go down as well as up so there is always a danger that you could get back less than you invest. Nothing here is personalised advice, if unsure you should seek advice.
  • Focus on quality companies delivering steady earnings growth has held back recent performance
  • Lowly-valued and more economically-sensitive sectors, which the manager has avoided, have outperformed
  • We rate David Dudding as a skilled and experienced manager in the European sector
  • There has been a change in leadership within the European stock market. The share prices of growth companies have raced ahead of their value-oriented peers for several years, but in recent months there has been a reversal of this trend.

    Amid economic uncertainty and low interest rates, many investors have been drawn to the safety of high-quality growth companies favoured for their dependable earnings and reliable dividends. With inflation expectations rising, which has historically led to rising interest rates, the yield and return available on more ‘defensive’ stocks appears less attractive. There has been a distinct shift in the performance of previously-popular growth sectors, such as consumer goods, healthcare, and technology, towards the once-disliked financials and commodity-related industries.

    Given its bias to high-quality companies with good growth prospects, the Threadneedle European Select Fund, managed by David Dudding, has recently underperformed the broader European market. Around one third of the fund is invested in consumer goods businesses, such as Unilever, while a bias towards the healthcare sector (15.4% of the fund) has held back performance.

    Shares in Novo Nordisk also struggled after the pharmaceuticals firm announced pricing challenges in the US and the loss of a large contract for one of its best-selling insulin drugs. The size of this investment has since reduced, although the manager maintains a smaller position as he still sees some long-term growth potential; the company is undertaking a review of drug-development projects and has announced plans to streamline its workforce.

    The recent change in the market environment has not altered the type of company David Dudding seeks. He believes the recent setback makes the share prices of many of these companies more attractive and is prepared to add to favoured investments during further periods of market weakness.

    Elsewhere, the manager continues to avoid businesses whose earnings are very sensitive to fluctuations in the economic cycle. Little of the portfolio is invested in sectors such as financials, which represents 8% of the fund compared with almost 22% for the benchmark. Overall the fund is a concentrated portfolio, which means each investment can have a significant impact on performance, but this is a higher-risk approach.


    It will take time before the full economic repercussions of major events, such as the EU referendum and the victory of Donald Trump in the US presidential election, become clear. David Dudding therefore believes stock markets across the globe will remain volatile in the short term.

    However, he also sees reasons for optimism. European markets could benefit from quantitative easing by the European Central Bank and low energy prices, which could put money in the pockets of consumers and reduce input costs for some businesses. Low interest rates and borrowing costs could also lead to a pickup in merger and acquisition activity. Overall, he continues to favour companies with robust earnings prospects and pricing power, which means they can often raise prices without significantly reducing demand for their products and services.

    Our view on this fund

    While the fund has underperformed the broader European market in the short term, longer term performance has been impressive. Under David Dudding’s stewardship since July 2008, the fund has grown 129.4%* compared with 66.9% for the FTSE World Europe ex UK Index, although please remember past performance is not a guide to future returns.

    Annual Percentage Growth
    Nov 11 -
    Nov 12
    Nov 12 -
    Nov 13
    Nov 13 -
    Nov 14
    Nov 14 -
    Nov 15
    Nov 15 -
    Nov 16
    Threadneedle European Select 24.9 19.9 7.7 6.6 8.0
    FTSE World Europe ex UK 13.8 26.9 5.7 0.2 12.1

    Source: *Lipper IM to 30/11/2016

    Past performance is not a guide to future returns.

    The manager’s focus on quality companies means the fund has tended to outperform during periods of market weakness, while it has also demonstrated less volatility than its peers. On the other hand, the fund may lag a rapidly rising market or when some of the more economically-sensitive areas of the market perform well, as seen recently.

    We continue to rate David Dudding as a skilled and experienced manager in the European sector and the fund features on the Wealth 150+ list of our favourite funds at the lowest ongoing charge. The Vantage charge of up to 0.45% also applies.

    Find out more about this fund including how to invest

    Please read the key features/key investor information document in addition to the information above.

    Important information - Please remember the value of investments, and any income from them, can fall as well as rise so you could get back less than you invest. This article is provided to help you make your own investment decisions, it is not advice. If you are unsure of the suitability of an investment for your circumstances please seek advice. No news or research item is a personal recommendation to deal.

    Want our latest research sent direct to your inbox?

    Our expert research team provide regular updates on a wide range of funds.

    Sign up today